Today we shared the U.S. FDA accepted for filing the sNDAs for casimersen and golodirsen. The sNDA submissions seek conversion of the accelerated approvals to traditional approvals and are supported by data from a confirmatory study, as well as published real-world evidence. Read more at Sarepta.com.

We’re at the 2026 ASGCT Annual Meeting in Boston, sharing updates with peers across the gene and cell therapy field. #ASGCT

Today we provided an update on financial results. Our CEO on Sarepta’s position:

Today we released our financial results for Q1 2026 and provided an update on clinical development programs. Read more at our website.

Today we announced early clinical results from Phase 1/2 ascending-dose studies of SRP-1001 for FSHD1 and SRP-1003 for DM1. The results demonstrated dose-dependent muscle exposure, early biomarker effects and favorable tolerability, reinforcing confidence in the potential for differentiated delivery capabilities of our platform. Learn more: bit.ly/4buZc1c

On Wednesday, March 25 at 8:30 am Eastern, we will host a live webcast to discuss first clinical results from two of our siRNA programs for neuromuscular diseases. Tune in here: investorrelations.sarepta.co…

News: Today we shared an update on our ongoing interactions with the U.S. FDA and intention to submit sNDAs seeking conversion of accelerated approvals to traditional approvals by the end of April. Visit our website for more information.

Happy to be here in Orlando at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference sharing updates and connecting with the community. Come find us! #MDAconference #MDA

Excited to be a partner of the 2026 Muscular Dystrophy Association Clinical & Scientific Conference. We’ll be there sharing updates on how Sarepta is advancing science and generating new insights for patients and healthcare providers. #MDAconference

Today, we released our financial results for Q4 and the full year of 2025. Our CEO on the results:

Today we announced positive topline three-year EMBARK results showing that our approved gene therapy significantly slows disease progression on key functional measures in ambulatory Duchenne patients. Read the release at Sarepta.com.

Today at #JPM26, CEO Doug Ingram discussed our preliminary Q4 and full-year 2025 performance and shared an update on corporate developments. Read more: bit.ly/3Nsdlm5

We just announced our preliminary fourth quarter and full-year 2025 net product revenues. Read more: bit.ly/3Nsdlm5

Sarepta announced the submission of its CTA for Study SRP-1005-101 to the New Zealand Medicines and Medical Devices Safety Authority. SRP-1005 is an investigational small interfering RNA (siRNA) therapeutic for the treatment of Huntington’s Disease. Read more: bit.ly/45lKgz5

Big news: Duchenne muscular dystrophy is now on the Recommended Uniform Screening Panel (RUSP)! This milestone reflects tireless advocacy from families, organizations and leaders committed to early diagnosis. Learn more: bit.ly/4aocNY4 #Newbornscreening

We just announced that the U.S. FDA approved to begin dosing in Cohort 8 of the ENDEAVOR study to evaluate the use of an enhanced immunosuppressive regimen as part of treatment with our gene therapy for non-ambulatory patients. Read the press release: bit.ly/3Kkhw22

Today we shared an update on the prescribing information for our approved gene therapy. Read the press release: bit.ly/4pvRmsr For U.S. residents

Today we released our financial results for Q3 2025 and provided an update on clinical development programs. Visit our website to learn more.

Attending #WMS2025? We will be presenting three oral presentations and five poster presentations at the 30th Annual International Congress of the World Muscle Society, taking place in Vienna, Austria, from Oct 7-11.